Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169112 | 0.91 | CA2 (0.50) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3685584 | 0.88 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1551243 | 0.88 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1146134 | 0.88 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2135574 | 0.88 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL17185508 | 0.88 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL22818194 | 0.88 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2493205 | 0.87 | CA2 (0.32) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1455645 | 0.87 | CA2 (0.38) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL17185512 | 0.82 | CA2 (0.32) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458903-B | Method for producing heteroaromatic sulfonamide compound | 宇部兴产株式会社 | 2021-02-05 | — | — | CN | claimed |
| EP-3156395-B1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE INDUSTRIES (JP) | 2019-01-09 | — | — | EP | claimed |
| US-20170121288-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | claimed |
| EP-3156395-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | UBE Industries, Ltd. (JP) | 2017-04-19 | — | — | EP | claimed |
| EP-3351548-B1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024106331-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING SULFONYL CHLORIDE AND METHOD FOR PRODUCING FLUORINE-CONTAINING SULFONYL FLUORIDE | ＡＧＣ株式会社 | 2024-05-23 | — | — | WO | disclosed |
| CN-111051278-B | Method for producing perfluoroalkyl sulfimide metal salt | 中央硝子株式会社 | 2022-05-13 | — | — | CN | disclosed |
| CN-108137638-B | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | 田边三菱制药株式会社 | 2022-05-03 | — | — | CN | disclosed |
| EP-3974436-A1 | CROSSLINKED NUCLEIC ACID GUNA METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| CN-112424647-A | Vehicle sensor including repellent surface, protective film, repellent coating composition, and method | 3M创新有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-111051278-A | Method for producing perfluoroalkyl sulfimide metal salt | 中央硝子株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-20150299132-A1 | AROMATIC IMIDE COMPOUND AND METHOD FOR PRODUCING SAME | AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9073828-B2 | Preparation method for perfluoroalkane sulfinate | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130137899-A1 | PROCESS FOR PRODUCING FLUORINE-CONTAINING SULFONYLIMIDE COMPOUND | MITSUBISHI MATERIALS ELECTRONIC CHEMICALS CO., LTD (JP) | 2013-05-30 | — | — | US | disclosed |
| EP-2289875-B1 | PROCESS FOR PRODUCING PERFLUOROALKANESULFINIC ACID SALT | CENTRAL GLASS CO LTD (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130023695-A1 | Preparation Method for Perfluoroalkane Sulfinate | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2543663-A1 | PREPARATION METHOD FOR PERFLUOROALKANE SULFINATE | Central Glass Company, Limited (JP) | 2013-01-09 | — | — | EP | disclosed |
| EP-2289875-A1 | PROCESS FOR PRODUCING PERFLUOROALKANESULFINIC ACID SALT | Central Glass Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
| US-RE29032-E | ANTIINFLAMMATORY AGENTS | RIKER LABORATORIES, INC. (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121288-A1 | METHOD FOR PRODUCING HETEROAROMATIC SULFONAMIDE COMPOUND | PFAS, SULT2A1, ARSA | CA2 102/4885CA1 62/4885MMP1 3889/4885 |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | POLRMT, POLM, NSUN2 | CA2 397/4885CA1 460/4885MMP1 3797/4885 |
| US-20130023695-A1 | Preparation Method for Perfluoroalkane Sulfinate | PFAS, PFKFB1, PFKFB2 | CA2 306/4885CA1 380/4885MMP1 2604/4885 |
| US-20150299132-A1 | AROMATIC IMIDE COMPOUND AND METHOD FOR PRODUCING SAME | H1-0, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4 | CA2 131/4885CA1 1693/4885MMP1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.